Trial · NCT04428385
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria
NCT04428385, Not applicable, Completed, Duke University; results first posted 2024-05-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria. Trials, record NCT04428385. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04428385
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria
- NCT number
- NCT04428385
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,205 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Malaria, Febrile Illness
- Interventions
- Testing incentive, Conditional artemisinin combination therapy subsidy
- First posted
- 2020-06-11
- Last updated
- 2024-05-06
- Results first posted
- 2024-05-06
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases | Day of enrollment | The number of all ACTs that are sold to malaria test-positive clients. |
| Secondary | Use of Malaria Rapid Diagnostic Test | Day of enrollment | Number of suspected malaria cases presenting to the retail outlet that are tested. |
| Secondary | Adherence to the RDT Result Among All Those Tested in the Shop | Day of enrollment | The number of tested participants who are adherent where adherence to the test result is defined as taking a quality-assured ACT if the RDT is positive or taking another drug (or no drug) if the test is negative |
| Secondary | Appropriate Case Management | Day of enrollment | Number of all suspected malaria cases that are managed appropriately (tested for malaria, use ACT following a positive test, and do not purchase an ACT after a negative test). |
| Secondary | ACT (Artemisinin Combination Therapy) Use Among Untested Participants | Day of enrollment | Number of participants who are not tested for malaria (did not test in the shop or have documentation of a test) and purchased an ACT. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases | Day of enrollment | Only participants who purchased ACTs were included in this analysis. Malaria test-positivity was based on mRDT testing testing at the outlet or documented testing brought to the facility. | ACTs | NUMBER |
| SECONDARY | Use of Malaria Rapid Diagnostic Test | Day of enrollment | Only participants who were suspected of having malaria were included in this analysis. This included anyone who tested for malaria or purchased antimalarials without a test. | suspected malaria cases | NUMBER |
| SECONDARY | Adherence to the RDT Result Among All Those Tested in the Shop | Day of enrollment | Only participants who tested at the outlet are included. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Appropriate Case Management | Day of enrollment | Only participants who were suspected of having malaria were included in this analysis. This included anyone who tested for malaria or purchased antimalarials without a test. | suspected malaria cases | NUMBER |
| SECONDARY | ACT (Artemisinin Combination Therapy) Use Among Untested Participants | Day of enrollment | Only untested participants are included. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases | Arm 1 (Control) | 49 | ACTs | ||
| ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases | Arm 2 (Consumer-directed and Provider-directed Intervention) | 49 | ACTs | ||
| Use of Malaria Rapid Diagnostic Test | Arm 1 (Control) | 226 | suspected malaria cases | ||
| Use of Malaria Rapid Diagnostic Test | Arm 2 (Consumer-directed and Provider-directed Intervention) | 217 | suspected malaria cases | ||
| Adherence to the RDT Result Among All Those Tested in the Shop | Arm 1 (Control) | 167 | Participants | ||
| Adherence to the RDT Result Among All Those Tested in the Shop | Arm 2 (Consumer-directed and Provider-directed Intervention) | 118 | Participants | ||
| Appropriate Case Management | Arm 1 (Control) | 167 | suspected malaria cases | ||
| Appropriate Case Management | Arm 2 (Consumer-directed and Provider-directed Intervention) | 118 | suspected malaria cases | ||
| ACT (Artemisinin Combination Therapy) Use Among Untested Participants | Arm 1 (Control) | 462 | Participants | ||
| ACT (Artemisinin Combination Therapy) Use Among Untested Participants | Arm 2 (Consumer-directed and Provider-directed Intervention) | 498 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1 (Control) | 1,101 | 24 |
| Overall Study | STARTED | Arm 2 (Consumer-directed and Provider-directed Intervention) | 1,104 | 24 |
| Overall Study | COMPLETED | Arm 1 (Control) | 1,101 | 24 |
| Overall Study | COMPLETED | Arm 2 (Consumer-directed and Provider-directed Intervention) | 1,104 | 24 |
| Overall Study | NOT COMPLETED | Arm 1 (Control) | 0 | 0 |
| Overall Study | NOT COMPLETED | Arm 2 (Consumer-directed and Provider-directed Intervention) | 0 | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 (Control) | 0 | 1,101 |
| Total, all-cause mortality | Arm 2 (Consumer-directed and Provider-directed Intervention) | 0 | 1,104 |
| Total, other adverse events | Arm 1 (Control) | 0 | 1,101 |
| Total, other adverse events | Arm 2 (Consumer-directed and Provider-directed Intervention) | 0 | 1,104 |
| Total, serious adverse events | Arm 1 (Control) | 0 | 1,101 |
| Total, serious adverse events | Arm 2 (Consumer-directed and Provider-directed Intervention) | 0 | 1,104 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33472650 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AI141444 | Malaria diagnostic testing and conditional subsidies to target ACTs in the retail sector: the TESTsmART trial | PRUDHOMMEOMEARA, WENDY | DUKE UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2018 to 2022 |
Source NIH RePORTER
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm 1 (Control) vs Arm 2 (Consumer-directed and Provider-directed Intervention): ACT (Artemisinin Combination Therapy) Use Among Untested Participants | Trial comparisons |
| Arm 1 (Control) vs Arm 2 (Consumer-directed and Provider-directed Intervention): Adherence to the RDT Result Among All Those Tested in the Shop | Trial comparisons |
| Arm 1 (Control) vs Arm 2 (Consumer-directed and Provider-directed Intervention): deaths from any cause | Trial comparisons |
| Arm 1 (Control) vs Arm 2 (Consumer-directed and Provider-directed Intervention): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04428385
GET https://conductscience.org/api/trials/v1/NCT04428385/registered